These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8304836)

  • 1. Betaseron for multiple sclerosis. Implications for therapeutics.
    Rudick RA
    Arch Neurol; 1994 Feb; 51(2):125-8. PubMed ID: 8304836
    [No Abstract]   [Full Text] [Related]  

  • 2. Betaseron advisory.
    Panitch HS
    Neurology; 1995 Jul; 45(7):1428-9. PubMed ID: 7617216
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 4. Nursing management of MS patients receiving interferon beta-1b therapy.
    Costello K; Conway K
    Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Neurology; 1994 Aug; 44(8):1537-40. PubMed ID: 8058168
    [No Abstract]   [Full Text] [Related]  

  • 6. Disease modifying treatment in multiple sclerosis.
    Fuller GN; Bone I
    J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
    [No Abstract]   [Full Text] [Related]  

  • 7. Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
    Río J; Montalban X
    Neurology; 2000 Apr; 54(8):1710. PubMed ID: 10762530
    [No Abstract]   [Full Text] [Related]  

  • 8. Interferon beta-1b.
    Rudge P
    Lancet; 1994 Nov; 344(8935):1511. PubMed ID: 7968150
    [No Abstract]   [Full Text] [Related]  

  • 9. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Benatar M
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424021
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of multiple sclerosis with interferon beta-1 b.
    Abdul-Ahad A; Shah S; Galazka A
    Neurology; 1997 Aug; 49(2):641-2. PubMed ID: 9270626
    [No Abstract]   [Full Text] [Related]  

  • 11. [Interferon therapy of multiple sclerosis. A question of the correct dose?].
    Hohlfeld R
    Nervenarzt; 2001 Feb; 72(2):67-8. PubMed ID: 11256156
    [No Abstract]   [Full Text] [Related]  

  • 12. Needed in MS: evidence, not EVIDENCE.
    Kieburtz K; McDermott M
    Neurology; 2002 Nov; 59(10):1482-3. PubMed ID: 12451186
    [No Abstract]   [Full Text] [Related]  

  • 13. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
    Rice G
    Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
    [No Abstract]   [Full Text] [Related]  

  • 14. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Betaseron: the new MS treatment.
    Kelley CL; Smeltzer SC
    J Neurosci Nurs; 1994 Feb; 26(1):52-6. PubMed ID: 8195651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treat early, but treat hard: Interferon-beta dose makes a difference.
    Mikol DD
    J Neuroophthalmol; 2001 Dec; 21(4):237-9. PubMed ID: 11756850
    [No Abstract]   [Full Text] [Related]  

  • 17. Interferon beta treatment for multiple sclerosis: persisting questions.
    Goodkin DE
    Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 19. Experiences with interferon-beta-1b treatment in MS after three year follow-up.
    Bencsik K; Rajda C; Füvesi J; Járdánházy T; Török M; Vécsei L
    Swiss Med Wkly; 2002 May; 132(17-18):237. PubMed ID: 12087490
    [No Abstract]   [Full Text] [Related]  

  • 20. Commentary on neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Whitaker JN
    Arch Neurol; 2001 Aug; 58(8):1301. PubMed ID: 11493175
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.